



Please support us
so we can continue
to make a positive
impact on people's lives

psoriasis
association

www.psoriasis-association.org.uk

The Psoriasis Association Registered Charity Numbers
1180666 and SC049563



OUR ACHIEVEMENTS
2025

psoriasis
association

REPORT FROM THE CHAIR

What a year 2025 has been for the Psoriasis Association - an organisation with a long history of supporting those with psoriasis.

"We are stronger than ever, supporting and empowering people with psoriasis, while funding ground-breaking research in the search for a cure."

Our story began in 1968, when local Consultant Dermatologist Dr Dick Coles, who was keen to bring people with psoriasis together to share experiences, established a psoriasis support group in his living room. From that first group in Northampton, a nationwide network of support groups followed. Fast forward to 2025 and we are stronger than ever, supporting and empowering people with psoriasis, while funding ground-breaking research in the search for a cure.

This Annual Report covers a significant period in our history, marked by the launch of our ambitious new five-year strategy for 2025–2030, which sits alongside our new Research Strategy for the same timeframe. Together, both strengthen our focus on supporting people affected by all forms of psoriasis, advancing care, driving impactful research and enhancing advocacy and public awareness.

A particular highlight was our Annual Meeting, held in London in June. The meeting, which was CPD accredited for the first time and delivered in collaboration with the St John's Institute of Dermatology, offered a programme showcasing Psoriasis Association-funded research and featuring high-quality panel discussions. Bringing together people with psoriasis, healthcare professionals and researchers, its record attendance ensured it was our most successful meeting to date.

We also remain proud of our research programme, which continues to be a central pillar of our work. Data collected through Researchfish demonstrated the strong impact of our funding, with more than half of our awards leading to further research investment. In 2025, researchers leveraged £613,076 in additional support underscoring the value and influence of our long-term commitment to research.

We continue to provide support for PhD Studentships and collaborative research projects. Work has progressed on the exciting UK epidemiology project, with early findings shared at the Annual Meeting. New funding was awarded for a project to assess the long-term impact of the Psoriasis Priority Setting Partnership's Top 10 Research Priorities (originally published in 2018), which continues to underpin all Psoriasis Association-funded PhD Studentships. A dedicated research project examining the lived experience of GPP began, helping to address evidence gaps for this rare and severe form of psoriasis.

Several new projects brought a renewed sense of excitement. Evidence gathered from our busy helplines, online forums, social media channels, and research findings continued to highlight persistent challenges in securing timely access to dermatology services. The Psoriasis Rapid Access to Care (PRAC) initiative developed in response, began work on a position statement that sets out what good, equitable access should look like in the UK.

A major redevelopment of PsoTeen, our dedicated resource for teenagers and young adults began. Funding was secured and work commissioned to ensure the relaunched PsoTeen reflects contemporary digital needs and is shaped by the views of young people, parents, and healthcare professionals.

Our commitment to providing high quality information was demonstrated through re-accreditation with the PIF Tick for the fifth consecutive year. Our dedicated and knowledgeable helpline staff continue to respond to enquiries with empathy and warmth, while our website and digital channels grew further, surpassing 61,000 followers during the year.

2025 was a year of strategic consolidation and forward momentum, characterised by strong collaboration, high impact research, influential access to care discussions, and a renewed focus on future generations. We are immensely proud to serve such a forward thinking and dedicated organisation, and look ahead to 2026 with confidence and optimism.



Helen McAteer
CEO



Dr Julia Schofield MBE
Chair of Trustees

INTRODUCTION

Making a difference to the lives of people affected by psoriasis and psoriatic arthritis for almost 60 years.

With a proud history of supporting people affected by all types of psoriasis, 2025 allowed us to take great strides forward in our mission to advance care, drive research, and enhance advocacy and public awareness.

Through the work of our [staff and trustees](#), the support of our [members](#) and the generosity of our [fundraisers](#) and individual [donors](#), we have been able to expand the range of services we offer and fund more ground-breaking research into psoriasis and its treatments.

“

“What a lot of people don't realise is where this membership money actually goes...it's not just a free pen or a newsletter. It helps fund research into the causes, treatments and hopefully one day a cure, supports people like us with trusted information, helplines and resources, and keeps pushing awareness so psoriasis is taken seriously”.

Sam

”



Who are we?

A national charity providing support and advocacy for all those affected by psoriasis and psoriatic arthritis over the last 58 years.

Our Vision

We envision a future where everyone affected by all types of psoriasis lives a healthier, more confident life, free from stigma, with access to effective care, **treatment**, and **support** – while we continue to strive towards a cure.

Our Mission

Our mission is to support individuals living with all types of psoriasis by advancing care, building a strong research base, and driving ground-breaking research forward to seek a cure. We strive to foster an inclusive society where those affected are understood, empowered, and supported, free from stigma and discrimination.

KEY ACHIEVEMENTS

Strategy and future proofing

Publication of 2025-2030 Strategy

Setting out a clear and ambitious framework for our future work, strengthening our focus on Supporting People, Driving Research and Advancing Care.

Major development of Psoteen

Work commenced on a project reflecting the needs of young people with psoriasis.

Publication of 2025-2030 Research Strategy

Ensuring we continue to invest in high quality research that will benefit people living with all types of psoriasis while also strengthening the field of psoriasis research.



2025

2025 Conference and AGM

Our most successful Conference to date with attendance at a record level

Recordings made available online

Extending reach post-conference for those that were unable to attend.

CPD accreditation offered for the first time

A popular addition demonstrating our commitment to teaching health professionals about psoriasis.

Presentations from several of our funded researchers

Supporting knowledge exchange and ensuring research findings reached local, national and international audiences, including people affected by psoriasis.

Research success & impact

Epidemiological research – Prof. Darren Ashcroft & University of Manchester

Major new study funded jointly by the Psoriasis Association and Global Psoriasis Atlas, continued investigating the incidence and prevalence of psoriasis in the UK. Findings were presented at the European Academy of Dermatology and Venereology (EADV) Annual Congress in Paris in September 2025.

Success for funded PhD students

2 Psoriasis Association funded students successfully defended their thesis' with 3 more students completing their PhD studentships.

Raising the profile of psoriasis research

Eighteen publications in peer-reviewed journals showing that outputs contribute to the global evidence base shaping psoriasis research and care.

Psoriasis Priority Setting Partnership

New ad hoc funding awarded to assess the long-term impact and uptake of the Partnership's Top 10 Research Priorities.

Dedicated research project into Generalised Pustular Psoriasis (GPP)

Examined the lived experience of those with GPP, helping to address evidence gaps for this rare and severe form of psoriasis.

Demonstrable impact of funding

Data from Researchfish demonstrated the strong impact of Psoriasis Association funding, with over half of awards leading to further research funding.

Development of Psoriasis Rapid Access to Care (PRAC) initiative

Work was started on a position statement to define what good, equitable access should look like across the UK.

Psoriasis Awareness Week 2025

Featured national radio and press coverage, virtual engagement events, including an online coffee morning and a webinar with St John's DermAcademy.

Influencing care, services and policy development

Providing patient evidence to the Scottish Medicines Consortium (SMC) and NICE and launching the Scottish Immune Medicated Inflammatory Diseases (IMID) survey as a cross-sector collaboration with four national charities.

Raising awareness and sharing reliable, accurate information

Achieved through our social media presence, which has now exceeded 61,000 followers across all platforms, and a fifth consecutive year of being awarded the PIF tick.

Advocacy and engagement



SUPPORTING PEOPLE, DRIVING RESEARCH, ADVANCING CARE

A brand-new strategy...

One of the year's most significant milestones was the launch of the Psoriasis Association's [2025-2030 Strategy](#), accompanied by the publication of our dedicated [Research Strategy](#). Together, these strategies set out a clear and ambitious framework for our future work, strengthening our focus on supporting people affected by psoriasis, advancing care, driving impactful research, enhancing advocacy and public awareness, and embedding collaboration and excellence across all activities.

They outline our aspirations for the next five years as we continue to make meaningful strides towards improving the lives of those affected by psoriasis, working steadily towards finding a cure, and reducing the stigma that often surrounds the condition.



Our Strategy articulates the Charity's Values - Empathy, Integrity, Collaboration, Excellence and Anti-Stigma - alongside five Strategic Priorities, strengthening consistency across awareness, policy, research and support activity.

The work we do is driven by 5 key values:



Our Five Core Strategic Priorities

1. Supporting People Affected by All Types of Psoriasis
2. Advancing Care for People with Psoriasis
3. Driving Research to Improve Outcomes
4. Enhancing Advocacy and Public Awareness
5. Celebrating 60 Years of Progress and Impact



"I struggle to put into words how appreciated the efforts of the Psoriasis Association are by those of us living with psoriatic disease. They see us and address our needs in ways others just don't".

Zoe






PROJECT SPOTLIGHT: PSORIASIS RAPID ACCESS TO CARE (PRAC) INITIATIVE

Significant progress was made during 2025 in addressing access to care, informed directly by lived experience. Evidence gathered from our helpline, forums and social media, alongside research findings, highlighted ongoing challenges in timely access to dermatology services.

Early in the year, our CEO met with a group of stakeholders, including clinicians, pharmaceutical companies and Integrated Care Board facilitators to discuss the need for, and options available for psoriasis rapid access clinics (PRAC's). It became evident that a clear, evidence-based position statement from the Psoriasis Association was required. Work commenced through a collaborative working agreement with UCB, involving people with lived experience, clinicians and pharmacists.

This led to the development of the Psoriasis Rapid Access to Care (PRAC) initiative, with work beginning on the position statement to define what good, equitable access should look like across the UK.

Initial work on this exciting project has already demonstrated the Psoriasis Association's ability to translate real-world patient experience into evidence-based, system-level advocacy.



“

“It's not just about having psoriasis, it's about the side that no one sees. The constant blood tests, the constantly low iron, the fatigue, nausea, the other side effects of medication, having to be careful of products you use including certain washing up liquids and hand soaps. The painful joints, questioning is this psoriatic arthritis developing. The mental side of having psoriasis is hard, the many questions that swim around your head when you're unable to sleep at night from being in pain, and the way it looks, wishing you had 'normal' skin rather than it being itchy, sore and bleeding”

Rhiannon

”



ANNUAL CONFERENCE & AGM 2025

SATURDAY 28TH JUNE

A brand-new venue with a brand-new feel

Held at prestigious County Hall in London, "The Right Treatment: Right Time Conference" welcomed healthcare professionals, Psoriasis Association members, non-members, trustees and officers. The conference was CPD certified for the first time, allowing attendees to earn CPD points to include in their portfolios.

Structured to encourage engagement and learning and featuring a mix of informative sessions and interactive discussions, the event also offered ample opportunities to network.



Showcasing our research

Professor Darren Ashcroft's keynote speech presented the findings of his Psoriasis Association funded Epidemiology of Psoriasis study. This exciting research, which was match-funded by the Global Psoriasis Atlas, has examined the demographics of who is affected by the condition in the UK.

Sylvia Zanesco presented findings from the APPLE study and shared her research on how diet and fasting can potentially play a role in managing psoriasis.

Luc Francis, a Computational Biologist, recently completed his Psoriasis Association funded PhD at the St John's Institute of Dermatology, King's College London. He presented an overview of the markers of remission in psoriasis, and the long-term implications of this research.

PSORIASIS AWARENESS WEEK 2025

WEDNESDAY 29TH OCTOBER - TUESDAY 4TH NOVEMBER 2025



This year our theme was the Comorbidities of Psoriasis.

Comorbidities are the presence of one or more additional diseases or disorders that occur in someone who is already living with psoriasis. They relate to conditions that you are more likely to have due to psoriasis including Psoriatic Arthritis, Cardiovascular Disease, Diabetes and the mental health impact that living with psoriasis may have.

We shared stories from [Wendy, Rhiannon, Jeremy and Antonia](#).



We unveiled our brand-new poster making it quicker and easier for people to access the support they need. It was distributed to GP surgeries as well as Dermatology and Rheumatology Departments and clinics.

Wednesday
We visited ASDA in Small Heath, Birmingham to meet people and discuss their psoriasis related concerns.



On World Psoriasis Day, we encouraged everyone to put on some purple to show their support for those with psoriasis and psoriatic arthritis.

Thursday - Diet and Nutrition

Research is growing to show that what we eat may play a role not only in managing symptoms, but also in supporting our overall health and any related conditions.



We teamed up with Dr Thivi Maruthappu (@drthivimaru), the UK's first dual-qualified dermatologist and nutritionist to discuss this issue. You can watch her expert insight on the link between diet and skin health in the [video](#) from her presentation at our Annual Conference.



Our colourful new infographic was released, espousing a Mediterranean diet and featuring examples of food groups that should be increased or decreased. The resource was produced with the help of Dr Thivi Maruthappu.

Monday - Psoriatic Arthritis Live Q&A with a Rheumatologist

We hosted a successful Instagram Live session by putting viewers questions to Rheumatologist, Professor Laura Coates from the HPOS Study (@hpos_study). The video is available on our YouTube channel.



Friday - Mental Health Virtual Coffee Morning

We held a virtual coffee morning via zoom on Friday 31st October which was a relaxed, informal chance for anyone to be able to hop on the call and connect and chat to others who are also living with psoriasis or psoriatic arthritis.



Mindfulness and Chocolate
Psychologist Dr Catherine O'Leary, who lives with psoriasis herself, produced a video for us, where she talked us through a mindfulness exercise that even involves eating some chocolate!

6th November

We held our annual collaborative webinar with the [St John's DermAcademy](#) focusing on understanding the link between body weight and psoriasis.

Tuesday - Research
For nearly 60 years, we have awarded millions of pounds in research grants and PhD Studentships thanks to the [fundraising](#) efforts of individual members, branches, legacies and private donations. We shared a number of resources including a [video interview](#) with Professor Pourzand from the University of Bath discussing her Hepcidin Research, details about our [grant call](#), the mySkin study and the new St John's Derm Academy [website](#).



RAISING AWARENESS AND SHARING RELIABLE, ACCURATE INFORMATION

With over 61,000 followers across all platforms, our vibrant social media presence helped lay the foundation for an effective year of communication.

Our confidential helpline service aims to provide information about all aspects of psoriasis and psoriatic arthritis, a listening ear, and

signposting to other organisations or services where appropriate.

You can call, email or WhatsApp us for help and support or visit either of our two websites: www.psoriasis-association.org.uk or www.psoteen.org.uk

We hold regular community information days in areas with high footfall and diverse audiences.

Offering over 50 information resources and leaflets, these are regularly reviewed to ensure they reflect current evidence, lived experience and emerging need. New resources on erythrodermic psoriasis and diet and nutrition were created in 2025.




Recordings from the Annual Meeting, Awareness Week and Instagram Live sessions are available on our YouTube channel and continue to be valuable resources.

We were re-accredited with the PIF Tick in March for the fifth consecutive year, confirming that our information meets rigorous standards for accuracy, reliability and transparency. Work continues to ensure all information resources remain within a three-year review cycle and are aligned with PIF Tick requirements.



A clip from Dr Manpreet Sagoo's Conference presentation at the 2025 Annual Meeting recorded over 45,700 views on TikTok, significantly extending the reach of clinical content.

A survey exploring the lived experience of GPP, funded by Boehringer Ingelheim, was commissioned. Findings will directly inform future information development once analysis is complete.



Collaborative working

We supported research led by Dermatology Clinical Nurse Specialist Polly Buchanan into waiting times and access to dermatology care for people with psoriasis in Scotland.

The findings, which were presented to a range of Scottish professional and policy groups, showed an average waiting time of **28** weeks from referral, with the longest reported wait of 26.5 months. One in five respondents reported being denied a dermatology referral due to lack of availability, and the same proportion experienced difficulties re-accessing care.

In the Autumn, we joined the National Rheumatoid Arthritis Society (NRAS), Crohn's & Colitis UK and Lupus UK to survey people in Scotland about their experiences of diagnosis, care and support.



Partnership Working

Ongoing work with the Arthritis and Musculoskeletal Alliance (ARMA), the British Association of Dermatologists (BAD), ALLIANCE in Scotland, NICE's People and Communities Team, strategic industry partners.

FUNDRAISING

22 fundraisers for 2025

100 mile walk in a month

Cake bake sales

4 day march in Netherlands

We had a number of marathons, half marathons and 10k's

10 runners in our PsoTeam at the London 10k

50th anniversary party

“

“I have decided to raise money for the Psoriasis Association because it's a cause very close to my heart. Every little fundraising effort helps to ensure research can happen to make our condition easier to live with and to hopefully find more treatments to help us.”

Rhiannon

”



www.psoteen.org.uk

PROJECT SPOTLIGHT: PSOTEEN REDESIGN

Major re-development of Psoteen

Work commenced on a large overhaul and redesign of our innovative resource for young people with psoriasis, involving genuine users to better reflect the needs of young people with psoriasis. This will bring it more into line with our main website and increase the resources on issues that specifically affect young people with psoriasis.



Living with psoriasis can be tough. In a recent survey of young people:



95% told us that their psoriasis had made them feel anxious or depressed



78% said psoriasis has had a negative effect on their social life



RESEARCH

Our commitment to advancing high quality psoriasis research continued throughout 2025, strengthening our role as a leading funder and advocate for research that improves the lives of people with psoriasis. This year, we launched an ambitious Research Strategy, supported a wide portfolio of studies, helped amplify the voices of people with psoriasis in national research initiatives, and celebrated several milestones from our funded students and researchers.

The 2025 Grant Call opened on 8 September and closed on 8 December, receiving strong interest across our funding streams:

- 7 PhD Studentship applications
- 6 Cecil King Memorial Award applications

Tharanyah Ketheeswaran



Kyle Diddams



Dr Esther BurdenTeh



We continued to fund a diverse and impactful portfolio comprising five PhD studentships and three small grant/Cecil King Memorial Award projects.

PhD Studentships

1. **Isabel Hyde** – University of Leeds, supervised by Professor Miriam Wittmann, Predicting therapy response in psoriasis
2. **Tharanyah Ketheeswaran** – King’s College London, supervised by Dr Paola Di Meglio, Studying biological variation in the environmental sensor and novel psoriasis drug target AHR
3. **Emmanuel Toni** – University of the West of England, supervised by Dr Ella Guest, Developing a social media intervention to increase awareness and reduce misconceptions about psoriasis
4. **Kyle Diddams** – King’s College London, supervised by Dr Satveer Mahil, Decoding inflammatory memory in psoriasis remission and recurrence
5. **Tom Clemmet** – University of Manchester, supervised by Dr Zenas Yiu, Cost-effectiveness of systemic therapies for psoriasis in the era of biosimilars

Emmanuel Toni



Tom Clemmet



Cecil King Memorial Awards

- **Dr Esther BurdenTeh** – University of Nottingham
Testing diagnostic criteria questionnaire for paediatric psoriasis (DIPSOCQC)
- **Dr Satveer Mahil** – King’s College London
Empowering early intervention through digital healthcare: The mySkin app

Small Grant

- **Dr Helen Young** – University of Manchester
Evaluating the impact of the Psoriasis Priority Setting Partnership (PSP)

Completed Research and Student Achievements

Two students successfully defended their theses in December 2025:



Heber Bright –
University of Manchester
Supervised by Dr Zenas Yiu

Risk of serious infection associated with IL17 and IL23 inhibitors compared with other biologics

“ Psoriasis is a long-term skin condition that is often treated with medicines that affect the immune system. While these treatments can be very effective, they may increase the risk of serious infections. Several newer treatments have become available in recent years, so it is important to understand how safe they are compared with older options.

This PhD research looked at whether different treatments for psoriasis are linked to serious infections. It used evidence from clinical trials and real-world patient data from a large UK psoriasis registry. The study examined both first and recurrent serious infections over time, as well as specific types of infections such as tuberculosis, meningitis, and fungal infections.

Overall, most treatments had similar risks of serious infection. One newer treatment, risankizumab, showed a lower risk than other treatments. In people with more severe psoriasis, infliximab was linked to a higher risk of serious infection compared with several other treatments. Certolizumab pegol was associated with a higher risk in women. Serious infections leading to death were very rare. Importantly, most patients continued their treatment even after experiencing a serious infection.

Different treatments were linked to different types of infections. TNF-alpha inhibitors, an older group of medicines, were more often associated with tuberculosis and meningitis, while IL-17 inhibitors, a newer group of medicine, were more commonly linked to a fungal skin infection called candidiasis. No major differences were seen for other fungal infections. One of the newer groups of medicines, IL-23 inhibitors, consistently showed lower risks in all comparisons.

These findings can help doctors and patients make more informed decisions when choosing psoriasis treatments, balancing benefits and potential infection risks.



Yiqiao Chen – University of Manchester
Supervised by Prof Silvia Bulfone-Paus

Mast cell-CD8 T cell interactions in psoriasis immunopathogenesis

“ Our research explored immune system changes in patients with mild-to-moderate psoriasis. We observed a reduction in memory CD8 T cells—key immune cells—in the bloodstream of these patients. Moreover, these cells displayed impaired function, suggesting they may be migrating from the bloodstream to the skin, where they contribute less effectively to disease control. Understanding the types and arrangement of cells in the skin during psoriasis is important for studying how immune cells interact with each other. We used a technique called imaging mass cytometry, a cutting-edge technique, which allows us to view the skin’s immune environment in detail. This method helped us identify how immune cells communicate with one another in both healthy skin and skin affected by psoriasis. This approach sheds light on the cellular mechanisms underlying psoriasis and may inform future therapeutic strategies.



Completed Small Grant

Professor Darren Ashcroft – University of Manchester
Examining the epidemiology and mortality of people with psoriasis



Contributions to Scientific Knowledge

Research supported by the Psoriasis Association resulted in publications across high impact journals in 2025, including:

- Journal of the European Academy of Dermatology & Venereology
- Journal of Investigative Dermatology
- JAMA Dermatology
- British Journal of Nutrition
- Proceedings of the Nutrition Society
- Nature Communications

These outputs deepen understanding of psoriasis biology, clinical management, and lived experience.

Launch of the 2025–2030 Research Strategy

In November, we unveiled our 2025–2030 Research Strategy, aligned to our organisational mission to improve outcomes for everyone affected by psoriasis. The strategy includes five core objectives:

1. Increase funding for psoriasis research through targeted grants and partnerships
2. Support collaborative research across universities, hospitals, and relevant partners
3. Address the Top 10 PSP priorities through continued funding and advocacy
4. Advance research into psychological wellbeing and quality of life
5. Identify research gaps and commission studies to address unmet needs

This strategy ensures our investments remain impactful, evidence driven, and focused on delivering meaningful benefits that reflect what is most important to people living with psoriasis.



Engaging the Community:

We continued to keep our community informed and engaged through:

- Grant updates and lay summaries in Pso Magazine
- Regular features on our website and social media channels
- Celebrating achievements shared by grant holders
- Showcasing research at our Annual Conference 2025, where PhD students Sylvia Zanesco and Luc Francis presented findings on diet/fasting and markers of remission, respectively

Funded researchers including Professors Darren Ashcroft and Catherine Smith also presented their latest work, highlighting progress and future directions in psoriasis research.

Advancing National Research: Our support for BSTOP

We continued our long-standing support for the **Biomarkers and Stratification To Optimise outcomes in Psoriasis (BSTOP)** study, initially pump-primed in 2011 and supported by a five-year maintenance grant from 2020.

BSTOP remains a major resource for national and international studies addressing PSP priorities, with achievements including:

- Integration of COVID19 and PsoProtect Me insights
- Identification of biomarkers predicting treatment response
- Outputs disseminated via high impact journals, conferences, and public facing materials
- Despite recruitment challenges common to large observational studies, the BSTOP team is innovating with remote self-reporting and at-home blood collection to expand participation

Supporting Research Participation and Patient and Public Involvement and Engagement (PPIE)

Our Research Network, comprising 141 members, played a vital role in supporting researchers through:

- Patient and Public Involvement and Engagement (PPIE)
- Recruitment support

We shared 16 research participation opportunities with our Research Network in 2025. Ensuring that research remains grounded in the experiences, needs, and priorities of people with psoriasis.

In 2025, the Psoriasis Association continued to deliver tangible impact by:

- Funding high quality research across biological, clinical, and psychological domains
- Supporting the next generation of psoriasis research leaders
- Strengthening national psoriasis research infrastructure
- Embedding patient voices in the research process
- Publishing and disseminating influential findings
- Delivering a long-term strategy to guide research investment to 2030

Together, these achievements demonstrate our ongoing commitment to improving understanding, treatment, and quality of life for everyone living with psoriasis.



FINANCIAL HIGHLIGHTS

This information is a summary of the full accounts of the Psoriasis Association for the period 1 January 2025 to 31 December 2025.

If you would like the full financial statements, Trustees annual report and Auditor's report please contact The Psoriasis Association or visit www.psoriasis-association.org.uk/who-we-are/funding

Income	2025 (£)	2024 (£)
Voluntary Income (including, for example, membership subscriptions, fundraising by individuals, Gift Aid, donations in memoriam)	82,025	98,871
Legacies	281,376	150,823
Investment Income	182,435	169,698
Income from Charitable Activities (including, for example, corporate sponsorship, charitable trust donations, Pso advertising)	83,573	50,153
Total Income for the Year	629,409	469,545

Expenditure	2025 (£)	2024 (£)
Raising Funds	88,100	82,267
Charitable Activities	677,716	476,615
Investment Management Costs	33,622	32,701
Total Expenditure for the Year	799,438	591,583

Voluntary Income

13%

Legacies

45%

Investment Income

29%

Charitable Activities

13%

Raising Funds

11%

Charitable Activities

85%

Investment Costs

4%



Total Net Assets	2025 (£)	2024 (£)
At 1st January	6,364,504	6,112,002
Add Incoming Resources	629,409	469,545
Deduct Net Resources Expended	799,438	591,583
(Losses)/Gains on Investment Assets	490,767	374,540
Gains on revaluation of Fixed Assets	5,000	NIL
At 31st December	6,690,242	6,364,504

Where does your money go?

We have a policy to hold at least 6 months charitable expenditure in free reserves at any one time (estimated at £275,000), and the free reserves in 2025 was actually **£352,567**

Long Term Funds

- Expendable Endowments – the result of earlier legacies and branch fundraising. **£5,279,275**
- Property – Head Office building of the Psoriasis Association. **£480,000**

Restricted Funds

- Restricted spend, for example on research or geographically. **£198,987**

Unrestricted Funds

- Designated spend – set aside by Trustees for specific projects. **£379,413**
- Reserves – held as buffer for emergencies. **£275,000**
- Additional unallocated reserves. **£77,567**



○ Long Term Funds

○ Restricted Funds

○ Unrestricted Funds

86%

3%

11%

OUR YEAR IN NUMBERS

60k

60k followers across all social media platforms



5 years of re-accreditation with the PIF TICK



Currently funding 5 PhD Studentships and 3 small grants

£231,921

Awarded £231,921 in new research grants

£286,536

Total spend on research

22k

22,000 registered forum users discussing 4,261 topics

4.2k+

14k+

Over 14k resource downloads from the website

1.1m+

Over 1.1M website page views

578k+

Over 578k website visitors

THANK YOU

All our members and supporters

Our Trustees

Dr Julia Schofield MBE, Gill Hynes, Brian Murkin, Steven Astaire, Adam Bushby, Sophie Field, Marie Fryers, Michael Israel, Lucy Moorhead, Susan Morgan, Dr Manisha Panchal.

Our Medical and Research Committee

Professor Nick Reynolds, Professor Catherine Smith, Professor Eugene Healy, Professor Tony Bewley, Professor Richard Weller, Dr Julia Schofield MBE, Dr Shane Solanky, Dr Elise Klein, Dr Catherine O'Leary.

...for helping us to have a successful 2025

People who donate towards our work with fundraising and gifts to mark special occasions

External Peer Reviewers

Professor Nicole Ward, Professor Lee Machado, Professor Laura Coates, Professor Richard Warren, Dr Satveer Mahil, Dr Sarah Morrow, Dr Ella Guest, Dr Alex Mizara, Dr David Gleeson, Dr Ravi Ramessur.

Staff

Helen McAteer, Laura Stevenson, Polly Matthews, Melinda Spencer, Georgia Sewell, Tass Miah (Until August 2025), Laura Bell and Diane Botterill.

People who leave legacies to the Psoriasis Association

Life Vice Presidents

Professor Terence Ryan, Professor Christopher Griffiths OBE, John Ford MBE, Professor Jonathan Barker, Nick Evans.

Trusts and Foundations who supported our work in 2025

Cecil King Memorial Foundation and the Marilyn Holzer Memorial Trust.

Companies who supported our work in 2025 via membership or unrestricted educational grants

Almirall, Boehringer Ingelheim, Dermal Laboratories Ltd, J & J Innovative Medicine, LEO Pharma, Medac Pharma, Novartis, Takeda and UCB.